Baird, G
Phase 2 trial (48 weeks, obesity population) Published in the New England Journal of Medicine (Jastreboff et al.), this trial enrolled 338 adults with a body mass index of 30 or higher, or 27-30 with at least one weight-related condition
Tampourlou, M., Trifanescu, R., Paluzzi, A., Ahmed, S
Finally, GLP-1RAs have also been associated with improvements in biochemical parameters, imaging markers, and histological features of fatty liver and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) (Nevola et al., 2023)
doi: Gorgojo-Martnez JJ, Mezquita-Raya P, Carretero-Gmez J, et al